The prognosis of patients with esophageal cancer is poor, due to frequent local recurrence and distant metastasis. The last decade has also seen that brachytherapy as a treatment with real potential to improve the therapeutic ratio of external irradiation. From March 1993 to October 1994 at the Institute of oncology and radiology in Belgrade, 18 patients with locally advanced esophageal cancer were treated by combined intralumenal brachytherapywith external beam irradiation. Median age was 59.6 years (range 43-70) and male/female ratio 2.6:1. Biopsy via endoscopy showed squamous cell carcinoma in 17 patients and adenocarcinoma in one case. External beam radiotherapywas applied on linear accelerator by locoregional texhnique with tumor dose of 30-60 Gy in 10-30 fractions. Intralumenal brachytherapy was eprformed on microselectron with tumor dose 5-20 Gy in 1-4 fractions. Response rate (complete response rate + partial response rate) was registrated in 13/18 (72%) patients. The good paliative effect for dysphagia, continuated passage for any food and increase body weight was shown in 16/18 (88%) patients. Six months after treatment, 7/13 patients were free of disease. Acute complications as irradiation pesophagitis occured in majority of patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A new NCL-targeting aptamer-drug conjugate as a promising therapy against esophageal cancer.
J Nanobiotechnology
January 2025
School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.
Esophageal cancer (EC) is one of the most common highly malignant tumors of the digestive system, with a poor prognosis under current treatment regimens. Nucleolin (NCL) is overexpressed in many tumors, and drugs specifically targeting NCL may offer a promising strategy for treating esophageal cancer. Here, we designed and prepared a novel aptamer-conjugated drug targeting NCL by AS1411 aptamer-human serum albumin (HSA)-the apoprotein of lidamycin (LDP)-active enediyne chromophore (AE), in order to achieve targeted treatment of esophageal cancer.
View Article and Find Full Text PDFValidation of mortality risk scores after esophagectomy.
J Cancer Res Clin Oncol
January 2025
Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Oncological esophagectomy is the mainstay in esophageal cancer treatment, but perioperative mortality remains a significant concern. Various scoring systems exist to identify patients at high risk for postoperative complications and death. In the following, we aim to evaluate and compare these different scoring systems.
View Article and Find Full Text PDFStructured surgical training in minimally invasive esophagectomy (MIE) increases textbook outcome-a risk-adjusted learning curve.
Surg Endosc
January 2025
Department of Surgery, Campus Charité Mitte Campus Virchow-Klinikum, Charité Universitätsmedizin Berlin, Berlin, Germany.
Background: Minimally Invasive Esophagectomy (MIE) is a complex surgical procedure that has become a cornerstone in the management of esophageal cancer. This study aims to delineate the learning curve associated with MIE and its impact on patient outcomes.
Methods: A retrospective analysis was conducted on 191 patients who underwent MIE between 2015 and 2022.
Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy.
Hum Vaccin Immunother
December 2025
Department of Oncology, Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
Human epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such as trastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. This review examines the mechanisms of drug resistance in HER2-positive G/GEJ cancer, the primary mechanisms of resistance explored include alterations in the HER2 receptor itself, such as mutations and changes in expression levels, as well as downstream signaling pathways, and interactions with the tumor microenvironment (TME). Furthermore, the review discusses the Novel therapeutic approaches, including the use of antibody-drug conjugates (ADCs) and combination therapies are assessed for their potential to enhance outcomes.
View Article and Find Full Text PDFThe prevalence of PD-L1 expression in patients with advanced oesophageal cancer: the EXCEED observational study.
J Clin Pathol
January 2025
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Aims: There are limited data on programmed death ligand 1 (PD-L1) expression in oesophageal cancer (OC) from multicentre studies conducted across China. We aimed to determine the prevalence of high PD-L1 expression in patients with advanced OC.
Methods: The EXCEED study was a multicentre, retrospective analysis of data from six tertiary hospitals that evaluated PD-L1 expression in adults with advanced OC or advanced head and neck squamous cell carcinoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!